NT 201 + Vibe System for Overactive Bladder

(RELIEVE Trial)

This trial tests a new treatment called NT 201 (a type of injection), used with the Vibe System, to determine its effectiveness for people with an overactive bladder. The trial aims to assess the treatment's safety, effectiveness, and optimal dosage. Participants will be randomly assigned to receive either the treatment or a placebo (inactive substance) for comparison. The trial seeks women diagnosed with idiopathic overactive bladder (OAB) for at least six months who experience frequent daily urination and incontinence. As a Phase 2 trial, the research focuses on evaluating the treatment's effectiveness in an initial, smaller group of people.

Research has shown that NT 201, which uses botulinum toxin, has been studied for safety in treating bladder problems. In earlier studies, patients generally tolerated this treatment well. For example, research on onabotulinumtoxinA (BOTOX®), a similar botulinum toxin, found it effective and safe for treating overactive bladder. These studies involved many participants and demonstrated significant improvements in bladder symptoms.

Researchers are excited about NT 201 combined with the Vibe System for treating overactive bladder because it offers a novel approach compared to standard treatments like anticholinergics or beta-3 adrenergic agonists. Unlike these medications, which typically target bladder muscle contractions, NT 201 is a botulinum toxin that works by relaxing the bladder muscles, potentially offering relief for patients who don't respond to current medications. Additionally, the Vibe System is an innovative catheter-based delivery method that could enhance the precision and effectiveness of the treatment, making it a promising option for those seeking alternatives to traditional oral medications.

Research has shown that NT 201, a type of botulinum toxin, can help treat overactive bladder (OAB). In earlier studies, patients who received botulinum toxin injections experienced a noticeable decrease in urinary incontinence, with symptoms reducing by up to 58% after six weeks, compared to a 35% reduction with a placebo. This treatment relaxes the bladder muscles, helping control the urge to urinate. In this trial, participants will receive either a lower dose of NT 201 (200U) or a higher dose (300U) in combination with the Vibe System. These findings suggest that NT 201, whether at 200U or 300U, could effectively manage OAB symptoms.²³⁶⁷⁸